dalteparin has been researched along with Kawasaki Disease in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 5.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| "The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly." | 1.62 | Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. ( Akat, H; Laloglu, F; Orbak, Z, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orbak, Z | 1 |
| Laloglu, F | 1 |
| Akat, H | 1 |
| Inamo, Y | 1 |
| Saito, K | 1 |
| Hasegawa, M | 1 |
| Hayashi, R | 1 |
| Nakamura, T | 1 |
| Abe, O | 1 |
| Ishikawa, T | 1 |
| Yoshino, Y | 1 |
| Hashimoto, K | 1 |
| Fuchigami, T | 1 |
2 other studies available for dalteparin and Kawasaki Disease
| Article | Year |
|---|---|
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Topics: Ampicillin; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; Azithromycin; Child; COVID-19; | 2021 |
Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.
Topics: Anticoagulants; Chemotherapy, Adjuvant; Child, Preschool; Coronary Artery Disease; Dalteparin; Femal | 2014 |